The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, ...
BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results